JP2016533172A - 細胞株からラブドウイルスを検出および除去する方法 - Google Patents

細胞株からラブドウイルスを検出および除去する方法 Download PDF

Info

Publication number
JP2016533172A
JP2016533172A JP2016520073A JP2016520073A JP2016533172A JP 2016533172 A JP2016533172 A JP 2016533172A JP 2016520073 A JP2016520073 A JP 2016520073A JP 2016520073 A JP2016520073 A JP 2016520073A JP 2016533172 A JP2016533172 A JP 2016533172A
Authority
JP
Japan
Prior art keywords
rhabdovirus
seq
rna
sequence
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016520073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016533172A5 (enExample
Inventor
ハイネス，ジョエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2016533172A publication Critical patent/JP2016533172A/ja
Publication of JP2016533172A5 publication Critical patent/JP2016533172A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C12N2760/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016520073A 2013-10-03 2014-10-03 細胞株からラブドウイルスを検出および除去する方法 Pending JP2016533172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886438P 2013-10-03 2013-10-03
US61/886,438 2013-10-03
PCT/US2014/059060 WO2015051255A1 (en) 2013-10-03 2014-10-03 Methods of detection and removal of rhabdoviruses from cell lines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019207576A Division JP2020036613A (ja) 2013-10-03 2019-11-18 細胞株からラブドウイルスを検出および除去する方法

Publications (2)

Publication Number Publication Date
JP2016533172A true JP2016533172A (ja) 2016-10-27
JP2016533172A5 JP2016533172A5 (enExample) 2019-03-22

Family

ID=52779185

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016520073A Pending JP2016533172A (ja) 2013-10-03 2014-10-03 細胞株からラブドウイルスを検出および除去する方法
JP2019207576A Ceased JP2020036613A (ja) 2013-10-03 2019-11-18 細胞株からラブドウイルスを検出および除去する方法
JP2021166782A Active JP7191175B2 (ja) 2013-10-03 2021-10-11 細胞株からラブドウイルスを検出および除去する方法
JP2022194791A Pending JP2023024506A (ja) 2013-10-03 2022-12-06 細胞株からラブドウイルスを検出および除去する方法
JP2023116327A Pending JP2023126495A (ja) 2013-10-03 2023-07-14 細胞株からラブドウイルスを検出および除去する方法
JP2024014113A Pending JP2024050747A (ja) 2013-10-03 2024-02-01 細胞株からラブドウイルスを検出および除去する方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019207576A Ceased JP2020036613A (ja) 2013-10-03 2019-11-18 細胞株からラブドウイルスを検出および除去する方法
JP2021166782A Active JP7191175B2 (ja) 2013-10-03 2021-10-11 細胞株からラブドウイルスを検出および除去する方法
JP2022194791A Pending JP2023024506A (ja) 2013-10-03 2022-12-06 細胞株からラブドウイルスを検出および除去する方法
JP2023116327A Pending JP2023126495A (ja) 2013-10-03 2023-07-14 細胞株からラブドウイルスを検出および除去する方法
JP2024014113A Pending JP2024050747A (ja) 2013-10-03 2024-02-01 細胞株からラブドウイルスを検出および除去する方法

Country Status (9)

Country Link
US (5) US10501500B2 (enExample)
EP (1) EP3052631B1 (enExample)
JP (6) JP2016533172A (enExample)
KR (2) KR102649950B1 (enExample)
CN (1) CN106103720A (enExample)
AU (3) AU2014329403B2 (enExample)
CA (1) CA2926225A1 (enExample)
SG (3) SG11201602585XA (enExample)
WO (1) WO2015051255A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518192A (ja) * 2022-03-01 2024-04-26 成都威斯克生物医▲薬▼有限公司 ラブドウイルス陰性スポドプテラ・フルギペルダ昆虫細胞系統、そのスクリーニング、その同定およびその使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103541A2 (en) * 2011-01-28 2012-08-02 Schlumberger Canada Limited Pipe damage interpretation system
WO2015051255A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) * 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
HUE051827T2 (hu) 2015-03-05 2021-03-29 Boehringer Ingelheim Animal Health Usa Inc Marker-rendszer, különösen baculovírus által expresszált alegység-antigénekhez
CN104962580B (zh) * 2015-06-30 2018-04-27 浙江大学 一种重组植物弹状病毒载体及其构建方法
EP4105321A1 (en) * 2015-11-01 2022-12-21 Glycobac, LLC Virus-free cell lines and methods for obtaining same
CN109182277B (zh) * 2018-09-07 2021-05-07 中国水产科学研究院长江水产研究所 一种黄鳝弹状病毒CrERV及RT-PCR检测引物及应用
EP3887756B1 (en) 2018-12-02 2025-07-23 Gentex Corporation Systems, devices and methods for micro-vibration data extraction using a time of flight (tof) imaging device
EP4100420A1 (en) 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies
EP4103699A1 (en) * 2020-02-10 2022-12-21 BioMarin Pharmaceutical Inc. Virus-free cell cultures
CN114686599A (zh) * 2020-12-30 2022-07-01 北京五加和基因科技有限公司 宿主昆虫细胞dna残留含量定量检测方法及试剂盒
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN118547114A (zh) * 2024-05-29 2024-08-27 长春生物制品研究所有限责任公司 一种用于Sf弹状病毒荧光定量检测的引物、探针、试剂盒及方法
CN120700212A (zh) * 2025-08-27 2025-09-26 北京昭衍生物技术有限公司 一种用于检测弹状病毒的qPCR引物探针组合物、试剂盒及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500602A (ja) * 1987-07-24 1991-02-14 カイロン　コーポレーション 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地
WO2010109920A1 (ja) * 2009-03-27 2010-09-30 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法
JP2011006489A (ja) * 2002-09-11 2011-01-13 Chugai Pharmaceut Co Ltd タンパク質精製方法
JP2012506239A (ja) * 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１８に結合する抗体およびそれを精製する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
JP2005168485A (ja) * 2003-11-20 2005-06-30 Tsutomu Suzuki ｓｉＲＮＡの設計方法
PL2601970T3 (pl) 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
US8481693B2 (en) 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
WO2009006450A1 (en) * 2007-06-29 2009-01-08 Boston Biomedical, Inc. Bacteria-mediated gene modulation via microrna machinery
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
EP2324113B8 (en) 2008-08-08 2018-04-04 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
KR102096937B1 (ko) 2011-07-11 2020-04-03 다케다 백신즈 인코포레이티드 비경구 노로바이러스 백신 제제
CN102605106B (zh) * 2012-03-29 2013-09-04 浙江省检验检疫科学技术研究院 蚕微孢子虫、核型多角体病毒和浓核病毒的三重荧光pcr检测方法及试剂盒和引物、探针
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
WO2015051255A1 (en) 2013-10-03 2015-04-09 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
EP4105321A1 (en) 2015-11-01 2022-12-21 Glycobac, LLC Virus-free cell lines and methods for obtaining same
CN114807009A (zh) 2022-03-28 2022-07-29 成都纳微金生物技术有限公司 一种不依赖血清的无弹状病毒污染的sf9细胞株、筛选方法及应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500602A (ja) * 1987-07-24 1991-02-14 カイロン　コーポレーション 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地
JP2011006489A (ja) * 2002-09-11 2011-01-13 Chugai Pharmaceut Co Ltd タンパク質精製方法
JP2012506239A (ja) * 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１８に結合する抗体およびそれを精製する方法
WO2010109920A1 (ja) * 2009-03-27 2010-09-30 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FY063436 CDNA LIBRARY FROM BMNPV-INFECTED BMN CELLS BOMBYX MORI CDNA CLONE BMNC30D11 3', MRNA SEQUEN, vol. [retireved on 2018-07-31], JPN6018030625, 2011, ISSN: 0004232884 *
J. GEN. VIROL., vol. 92, JPN6018030624, 2011, pages 200 - 203, ISSN: 0004232883 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518192A (ja) * 2022-03-01 2024-04-26 成都威斯克生物医▲薬▼有限公司 ラブドウイルス陰性スポドプテラ・フルギペルダ昆虫細胞系統、そのスクリーニング、その同定およびその使用
JP7733748B2 (ja) 2022-03-01 2025-09-03 成都威斯克生物医▲薬▼有限公司 ラブドウイルス陰性スポドプテラ・フルギペルダ昆虫細胞系統、そのスクリーニング、その同定およびその使用

Also Published As

Publication number Publication date
CN106103720A (zh) 2016-11-09
EP3052631B1 (en) 2019-08-07
AU2022259826A1 (en) 2023-01-19
US20230303633A1 (en) 2023-09-28
AU2022259826B2 (en) 2025-01-02
KR20210154988A (ko) 2021-12-21
AU2014329403B2 (en) 2020-10-08
JP2022009010A (ja) 2022-01-14
AU2014329403A1 (en) 2016-05-05
WO2015051255A1 (en) 2015-04-09
SG11201602585XA (en) 2016-05-30
JP2024050747A (ja) 2024-04-10
AU2020294216B2 (en) 2022-11-24
US20250109172A1 (en) 2025-04-03
AU2020294216A1 (en) 2021-01-28
EP3052631A4 (en) 2017-06-14
US12018052B2 (en) 2024-06-25
JP2023126495A (ja) 2023-09-07
US11286282B2 (en) 2022-03-29
SG10201802772YA (en) 2018-05-30
JP7191175B2 (ja) 2022-12-16
US12006341B2 (en) 2024-06-11
KR20160062049A (ko) 2016-06-01
EP3052631A1 (en) 2016-08-10
KR102474663B1 (ko) 2022-12-07
JP2023024506A (ja) 2023-02-16
KR102649950B1 (ko) 2024-03-22
JP2020036613A (ja) 2020-03-12
US20200190146A1 (en) 2020-06-18
US20220213150A1 (en) 2022-07-07
US10501500B2 (en) 2019-12-10
CA2926225A1 (en) 2015-04-09
SG10202107054TA (en) 2021-08-30
US20160244487A1 (en) 2016-08-25
US12479891B2 (en) 2025-11-25

Similar Documents

Publication Publication Date Title
JP7191175B2 (ja) 細胞株からラブドウイルスを検出および除去する方法
Uchida et al. Rapid and sensitive detection of mumps virus RNA directly from clinical samples by real‐time PCR
Sathyabhama et al. ‘PmLyO-Sf9-WSSV complex’could be a platform for elucidating the mechanism of viral entry, cellular apoptosis and replication impediments
JP2008527997A (ja) 核酸の抽出及び同定方法
JP6734137B2 (ja) インビトロにおいて生成したウイルスの精製方法及びウイルスのクリアランスアッセイ
Tham et al. Polymerase chain reaction amplification and gene sequence analysis of a calicivirus from a feral rabbit
Hassanien et al. Isolation, antigenic and molecular characterization of sheeppox virus from clinical cases in Egypt
HK1227433A1 (en) Methods of detection and removal of rhabdoviruses from cell lines
HK1227433B (en) Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) 粒子に含まれる逆転写酵素活性の検出
Si et al. Adaptation of genotype 3 hepatitis E virus in Eastern China and inverse correlation with genotype 4 hepatitis E virus
HK1231118B (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
HK1231118A1 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190107

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191121

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20191211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200121

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200317

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200730

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201001

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20201001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201225

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210401

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210428

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210428